THC/CBD spray reduced cannabis withdrawal symptoms in a clinical trial

Two-site, double-blind, randomized clinical trial with inpatient and outpatient phases. 51 cannabis-dependent adults received a 6-day nabiximols or placebo regimen with standardized psychosocial interventions during a 9-day admission, followed by 28-day outpatient follow-up. Primary outcomes included withdrawal severity (Cannabis Withdrawal Scale), treatment retention, and adverse events.

No medications are approved for cannabis dependence or withdrawal. This trial, published in JAMA Psychiatry, demonstrated that agonist replacement with nabiximols can manage the acute withdrawal period effectively. The finding that withdrawal relief did not translate to better long-term outcomes echoes patterns seen with other substance use disorders.

This study positioned nabiximols as a potential withdrawal management tool similar to how nicotine replacement is used for smoking cessation. The gap between short-term withdrawal management and long-term use reduction mirrors challenges across addiction medicine and suggests that medication alone may be insufficient without sustained behavioral support.

Small sample size of 51 participants limits statistical power. The 6-day medication course may have been too short. Inpatient setting does not reflect typical outpatient treatment conditions. Long-term outcomes were based on self-report.